Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
国家癌症研究所、国家临床试验网络 U10 首席学术网站
基本信息
- 批准号:8846075
- 负责人:
- 金额:$ 129.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-05-06 至 2019-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAmerican College of Radiology Imaging NetworkAmerican College of Surgeons Oncology GroupCancer and Leukemia Group BClinicClinic ActivityClinical ResearchClinical TrialsClinical Trials NetworkCollectionDataEastern Cooperative Oncology GroupGoalsGrantGynecologic Oncology GroupHealthImageInstitutesInstitutionJournalsLeadLeadershipMalignant NeoplasmsMayo Clinic Cancer CenterNorth Central Cancer Treatment GroupPatientsPublishingRadiation Therapy Oncology GroupReportingResearchResearch InfrastructureResearch PersonnelRoleSiteStructureSupport SystemUnited States National Institutes of HealthWorkbaseburden of illnessmember
项目摘要
DESCRIPTION (provided by applicant): Mayo Clinic has had a long-standing commitment to support and lead NCTN clinical trials through NCCTG, ECOG, ACOSOG, ACRIN, RTOG, and GOG. Mayo Clinic served as the founding institution and operational base for NCCTG until its merger with CALGB and ACOSOG to form the Alliance. Mayo investigators have also had leadership roles in these groups as well as in the newly forming groups (Alliance, ECOG-ACRIN, and NRG). The current clinical research structure within the Mayo Clinic Cancer Center (MCCC) continues to prioritize NIH sponsored trial, including NCTN trials, over other trials. Support systems are in place within the MCCC to maximize accrual and to support the translational components of these trials, including biospecimen collection and imaging. Mayo investigators also remained very active in trial leadership. Mayo investigators have also been very effective in utilizing data and biospecimens collected from NCTN trials to address important and relevant research questions. Through this commitment to research, Mayo investigators have published multiple reports in high impact journals and successfully obtained multiple grants, including R01 grants, to support this work.
描述(由申请人提供):马约诊所长期致力于通过NCCTG、ECOG、ACOSOG、ACRIN、RTOG和GOG支持和领导NCTN临床试验。马约诊所是NCCTG的创始机构和运营基地,直到它与CALGB和ACOSOG合并形成联盟。马约研究人员还在这些小组以及新成立的小组(联盟、ECOG-ACRIN和NRG)中发挥领导作用。马约诊所癌症中心(MCCC)目前的临床研究结构继续优先考虑NIH申办的试验,包括NCTN试验,而不是其他试验。MCCC内设有支持系统,以最大限度地增加应计费用,并支持这些试验的翻译部分,包括生物标本采集和成像。马约调查员在审判领导方面也非常积极。马约的研究人员也非常有效地利用从NCTN试验中收集的数据和生物标本来解决重要和相关的研究问题。通过这种对研究的承诺,马约研究人员在高影响力期刊上发表了多篇报告,并成功获得了多项赠款,包括R 01赠款,以支持这项工作。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEVEN R ALBERTS其他文献
STEVEN R ALBERTS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEVEN R ALBERTS', 18)}}的其他基金
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1
NCI,国家临床试验网络牵头学术参与站点 (LAPS) UG1
- 批准号:
9914075 - 财政年份:2019
- 资助金额:
$ 129.59万 - 项目类别:
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1
NCI,国家临床试验网络牵头学术参与站点 (LAPS) UG1
- 批准号:
10115645 - 财政年份:2019
- 资助金额:
$ 129.59万 - 项目类别:
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1
NCI,国家临床试验网络牵头学术参与站点 (LAPS) UG1
- 批准号:
10582519 - 财政年份:2019
- 资助金额:
$ 129.59万 - 项目类别:
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1
NCI,国家临床试验网络牵头学术参与站点 (LAPS) UG1
- 批准号:
10356075 - 财政年份:2019
- 资助金额:
$ 129.59万 - 项目类别:
NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1
NCI,国家临床试验网络牵头学术参与站点 (LAPS) UG1
- 批准号:
10062104 - 财政年份:2019
- 资助金额:
$ 129.59万 - 项目类别:
Project 3: Inhibition of SCD1 as a therapeutic strategy for HCC
项目 3:抑制 SCD1 作为 HCC 的治疗策略
- 批准号:
10251134 - 财政年份:2018
- 资助金额:
$ 129.59万 - 项目类别:
Project 3: Inhibition of SCD1 as a therapeutic strategy for HCC
项目 3:抑制 SCD1 作为 HCC 的治疗策略
- 批准号:
10468831 - 财政年份:2018
- 资助金额:
$ 129.59万 - 项目类别:
Project 3: Inhibition of SCD1 as a therapeutic strategy for HCC
项目 3:抑制 SCD1 作为 HCC 的治疗策略
- 批准号:
10006084 - 财政年份:2018
- 资助金额:
$ 129.59万 - 项目类别: